All In Biotech

Drug Trial Radar · NCT02576574

Avelumab in First-line NSCLC (JAVELIN Lung 100)

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,214

Actual

Start

Oct 29, 2015

Primary completion

Dec 6, 2021

Study completion Jan 29, 2024

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Oct 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.

Conditions

  • First Line Non-Small Cell Lung Cancer

Interventions

  • AvelumabDrug

    Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.

  • PemetrexedDrug

    Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

  • PaclitaxelDrug

    Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

  • GemcitabineDrug

    Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.

  • GemcitabineDrug

    Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.

  • CarboplatinDrug

    Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.

  • CisplatinDrug

    Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.

  • CarboplatinDrug

    Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.

  • Avelumab WeeklyDrug

    Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
  2. Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
  3. Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)
  4. Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)Time frame: Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)

Locations

349 sites in 42 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Arizona Center for Cancer Care

    Surprise, Arizona

  • Sharp Memorial Hospital

    San Diego, California

  • University Cancer Institute

    Boynton Beach, Florida

  • South Georgia Medical Center

    Valdosta, Georgia

  • Christus Cancer Treatment Center

    Shreveport, Louisiana

  • Henry Ford Hospital

    Detroit, Michigan

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • Nevada Cancer Research Foundation

    Las Vegas, Nevada

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Novant Health Oncology Specialists

    Kernersville, North Carolina

  • Mercy Research

    Oklahoma City, Oklahoma

  • Kaiser Permanente Northwest

    Portland, Oregon

  • Lancaster Cancer Center

    Lancaster, Pennsylvania

  • Cookeville Regional Medical Center

    Cookeville, Tennessee

  • Thompson Cancer Survival Center

    Knoxville, Tennessee

  • Coastal Bend Cancer Center

    Corpus Christi, Texas

  • Oncology Consultants, P.A.

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • Cheyenne Regional Medical Center

    Cheyenne, Wyoming

  • Albury Wodonga Regional Cancer Centre

    Albury, New South Wales, Australia

  • Coffs Harbour Health Campus

    Coffs Harbour, New South Wales, Australia

  • St George Private Hospital

    Kogarah, New South Wales, Australia

  • Lismore Base Hospital

    Lismore, New South Wales, Australia

  • Orange Health Service

    Orange, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Gallipoli Medical Research Foundation Ltd

    Greenslopes, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Ballarat Base Hospital

    Ballarat, Victoria, Australia

  • Bendigo Hospital

    Bendigo, Victoria, Australia

  • South West Healthcare

    Warrnambool, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • ZNA Middelheim

    Antwerp, Belgium

  • A.Z. Klina

    Brasschaat, Belgium

  • CHU Ambroise Paré

    Mons, Belgium

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, Brazil

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

Showing 40 of 349 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.